Page 34 - AN-4-4

Advanced Neurology Graphene quantum dots approach in AD

cognitive deficit in a mouse model of Alzheimer disease 65. Xiao S, Zhou D, Luan P, et al. Graphene quantum dots
with plaques and tangles. Ann Neurol. 2014;75(6):851-863. conjugated neuroprotective peptide improve learning and
memory capability. Biomaterials. 2016;106:98-110.
doi: 10.1002/ana.24145
doi: 10.1016/j.biomaterials.2016.08.021
54. Andra A, Tanigawa S, Bito T, Ishihara A, Watanabe F,
Yabuta Y. Effects of vitamin B12 deficiency on amyloid-β 66. Perini G, Palmieri V, Ciasca G, De Spirito M, Papi M.
toxicity in Caenorhabditis elegans. Antioxidants. Unravelling the potential of graphene quantum
2021;10(6):962. dots in biomedicine and neuroscience. Int J Mol Sci.
2020;21(10):3712.
doi: 10.3390/antiox10060962
doi: 10.3390/ijms21103712
55. Iqbal K, Alonso AD, Gong CX, Khatoon S, Singh TJ,
Grundke-Iqbal I. Mechanism of neurofibrillary degeneration 67. Tang H, Li Y, Kakinen A, et al. Graphene quantum dots
in Alzheimer’s disease. Mol Neurobiol. 1994;9(1-3):119-123. obstruct the membrane axis of Alzheimer’s amyloid beta.
doi: 10.1007/BF02816111 Phys Chem Chem Phys. 2021;24(1):86-97.
56. Brion JP. Neurofibrillary tangles and Alzheimer’s disease. doi: 10.1039/D1CP04246G
Eur Neurol. 1998;40(3):130-140. 68. Walton-Raaby M, Woods R, Kalyaanamoorthy S.
doi: 10.1159/000007969 Investigating the theranostic potential of graphene quantum
dots in Alzheimer’s disease. Int J Mol Sci. 2023;24(11):9476.
57. Di Lorenzo D. Tau protein and tauopathies: Exploring
tau protein-protein and microtubule interactions, cross- doi: 10.3390/ijms24119476
interactions and therapeutic strategies. ChemMedChem. 69. Zhang Y, Zhu R, Rajewski B, et al. Graphene Quantum
2024;19(21):e202400180. Dots Prevent the Amyloidogenic Tau Protein Aggregation in
doi: 10.1002/cmdc.202400180 Alzheimer’s Disease. AIChE Annual Meeting; 2022.
58. Kamboh MI. Molecular genetics of late-onset Alzheimer’s 70. Tabish TA, Scotton CJ, Ferguson DC, et al. Biocompatibility
disease. Ann Hum Genet. 2004;68(4):381-404. and toxicity of graphene quantum dots for potential
application in photodynamic therapy. Nanomedicine.
doi: 10.1046/j.1529-8817.2004.00110.x 2018;13(15):1923-1937.
59. Isik AT. Late-onset Alzheimer’s disease in older people. Clin doi: 10.2217/nnm-2018-0018
Interv Aging. 2010;5:307-311.
71. Long JM, Holtzman DM. Alzheimer disease: An
doi: 10.2147/CIA.S11718 update on pathobiology and treatment strategies. Cell.
60. Dorszewska J, Prendecki M, Oczkowska A, Dezor M, 2019;179(2):312-339.
Kozubski W. Molecular basis of familial and sporadic doi: 10.1016/j.cell.2019.09.001
Alzheimer’s disease. Curr Alzheimer Res. 2016;13(9):952-963.
72. Nurunnabi M, Khatun Z, Huh KM, et al. In vivo
doi: 10.2174/1567205013666160314150501 biodistribution and toxicology of carboxylated graphene
61. Piaceri I, Nacmias B, Sorbi S. Genetics of familial and quantum dots. ACS Nano. 2013;7(8):6858-6867.
sporadic Alzheimer’s disease. Front Biosci (Elite Ed). doi: 10.1021/nn402043c
2013;5(1):167-177.
73. Yuan X, Liu Z, Guo Z, Ji Y, Jin M, Wang X. Cellular
doi: 10.2741/e605
distribution and cytotoxicity of graphene quantum dots with
62. Hickman SE, El Khoury J. TREM2 and the neuroimmunology different functional groups. Nanoscale Res Lett. 2014;9:108.
of Alzheimer’s disease. Biochem Pharmacol. 2014;88(4):495-498.
doi: 10.1186/1556-276X-9-108
doi: 10.1016/j.bcp.2013.11.021
74. Chong Y, Ma Y, Shen H, et al. The in vitro and in vivo toxicity of
63. Price DL, Sisodia SS. Mutant genes in familial Alzheimer’s graphene quantum dots. Biomaterials. 2014;35(19):5041-5048.
disease and transgenic models. Annu Rev Neurosci. doi: 10.1016/j.biomaterials.2014.03.021
1998;21:479-505.
75. Karch CM, Goate AM. Alzheimer’s disease risk genes
doi: 10.1146/annurev.neuro.21.1.479
and mechanisms of disease pathogenesis. Biol Psychiatry.
64. Liu CG, Song J, Zhang YQ, Wang PC. MicroRNA-193b 2015;77(1):43-51.
is a regulator of amyloid precursor protein in the blood doi: 10.1016/j.biopsych.2014.05.006
and cerebrospinal fluid derived exosomal microRNA-
193b is a biomarker of Alzheimer’s disease. Mol Med 76. Alzheimer’s Association. Alzheimer’s disease facts and
Rep. 2014;10(5):2395-2400. figures. Alzheimers Dement. 2015;11(3):332.
doi: 10.3892/mmr.2014.2484 doi: 10.1016/j.jalz.2015.02.003

Volume 4 Issue 4 (2025) 28 doi: 10.36922/an.7087